Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)

About Xenon Pharmaceuticals

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company's platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XENE
  • CUSIP:
Key Metrics:
  • Previous Close: $7.75
  • 50 Day Moving Average: $8.19
  • 200 Day Moving Average: $8.05
  • 52-Week Range: $5.65 - $8.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.01
  • P/E Growth: -0.09
  • Market Cap: $138.67M
  • Outstanding Shares: 17,893,000
  • Beta: 1.44
Profitability:
  • Net Margins: -449.72%
  • Return on Equity: -34.72%
  • Return on Assets: -32.94%
Debt:
  • Current Ratio: 17.97%
  • Quick Ratio: 17.97%
Additional Links:
Companies Related to Xenon Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Xenon Pharmaceuticals (NASDAQ:XENE) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.30 (110.32% upside)

Analysts' Ratings History for Xenon Pharmaceuticals (NASDAQ:XENE)
Show:
DateFirmActionRatingPrice TargetDetails
1/19/2017Jefferies Group LLCSet Price TargetBuy$13.00View Rating Details
12/22/2016Bloom BurtonInitiated CoverageBuy$14.50View Rating Details
10/21/2016Stifel NicolausInitiated CoverageBuy$18.00View Rating Details
9/26/2016GuggenheimInitiated CoverageBuy -> Buy$20.00View Rating Details
8/5/2016Canaccord GenuityReiterated RatingBuy$16.00View Rating Details
9/24/2015SEB Equity ResearchReiterated RatingPositiveView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/3/2016Q316($0.43)($0.51)$2.20 millionViewListenView Earnings Details
8/3/2016Q216($0.48)($0.42)$2.25 millionViewN/AView Earnings Details
5/10/2016Q116($0.21)($0.23)$3.30 millionViewListenView Earnings Details
3/8/2016Q415($0.16)($0.27)$4.65 millionViewListenView Earnings Details
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details
8/10/2015Q215($0.16)($0.07)$4.23 millionViewListenView Earnings Details
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details
3/12/2015Q4($0.09)$1.57ViewListenView Earnings Details
12/16/2014$0.41$1.69ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)
Current Year EPS Consensus Estimate: $-1.52 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.21)($0.21)($0.21)
Q2 20161($0.24)($0.24)($0.24)
Q3 20161($0.47)($0.47)($0.47)
Q4 20161($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Xenon Pharmaceuticals (NASDAQ:XENE)
Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 55.34%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Frank A HollerDirectorSell30,000$7.85$235,500.00View SEC Filing  
8/19/2016Frank A HollerDirectorSell11,938$7.65$91,325.70View SEC Filing  
8/18/2016Frank A HollerDirectorSell18,062$7.93$143,231.66View SEC Filing  
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.00View SEC Filing  
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.12View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Xenon Pharmaceuticals (NASDAQ:XENE)
DateHeadline
finance.yahoo.com logoXenon Pharmaceuticals Outlines Key Milestones for 2017 (NASDAQ:XENE)
finance.yahoo.com - February 25 at 4:34 AM
News IconXenon Pharmaceuticals Inc XENE Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:XENE)
www.bioportfolio.com - February 20 at 7:40 PM
News IconXenon Pharmaceuticals Inc XENE Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 19122016] Prices from USD $250 (NASDAQ:XENE)
www.bioportfolio.com - January 27 at 4:12 PM
tmcnet.com logoTrue North Provides Corporate Update at J.P. Morgan Healthcare Conference (NASDAQ:XENE)
www.tmcnet.com - January 11 at 2:27 AM
us.rd.yahoo.com logo4:39 am Xenon Pharmaceuticals outlines key milestones for 2017; expects topline data from XEN801 Phase 2 clinical trial for acne (NASDAQ:XENE)
us.rd.yahoo.com - January 9 at 3:23 PM
rttnews.com logoEXAS Abuzz, MACK Makes Deal With Ipsen, XENE Awaits Data (NASDAQ:XENE)
www.rttnews.com - January 9 at 4:50 AM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events (NASDAQ:XENE)
biz.yahoo.com - January 4 at 7:51 AM
insidermonkey.com logoHow Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers (NASDAQ:XENE)
www.insidermonkey.com - December 20 at 8:57 AM
finance.yahoo.com logoWilbur Ross Sells 2 Holdings, Trims Another (NASDAQ:XENE)
finance.yahoo.com - December 1 at 10:04 PM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 3-Nov-16 8:30pm GMT (NASDAQ:XENE)
finance.yahoo.com - November 29 at 1:26 PM
finance.yahoo.com logoXENON PHARMACEUTICALS INC. Financials (NASDAQ:XENE)
finance.yahoo.com - November 23 at 8:40 PM
News IconXenon Pharmaceuticals Inc. XENE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:XENE)
www.bioportfolio.com - November 23 at 11:55 AM
News IconXenon Pharmaceuticals Inc. XENE Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:XENE)
www.bioportfolio.com - November 22 at 8:39 PM
finance.yahoo.com logoXenon Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference (NASDAQ:XENE)
finance.yahoo.com - November 8 at 8:29 PM
capitalcube.com logoXenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016 (NASDAQ:XENE)
www.capitalcube.com - November 8 at 1:23 PM
einnews.com logoXenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:XENE)
world.einnews.com - November 5 at 8:01 PM
biz.yahoo.com logoQ3 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:XENE)
biz.yahoo.com - November 3 at 12:49 PM
publicnow.com logoXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update (NASDAQ:XENE)
www.publicnow.com - October 27 at 8:25 PM
finance.yahoo.com logoCoverage initiated on Xenon Pharmaceuticals by Guggenheim (NASDAQ:XENE)
finance.yahoo.com - September 26 at 8:08 PM
News IconXenon Pharmaceuticals Announces Closing of $34.5 Million Public Offering (NASDAQ:XENE)
www.bctechnology.com - September 21 at 12:02 PM
News IconXenon pharmaceuticals reports second quarter 2016 financial results and provides corporate update nasdaq_xene data recovery nj (NASDAQ:XENE)
handyrecovery.in - September 19 at 3:15 PM
4-traders.com logoXenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:XENE)
www.4-traders.com - September 17 at 7:32 PM
publicnow.com logoXenon Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Closing of $34.5 Million Public Offering (NASDAQ:XENE)
www.publicnow.com - September 14 at 12:34 PM
News IconXenon Pharmaceuticals Inc. (XENE): Biotechnology Value Fund Adds More Shares (NASDAQ:XENE)
feedproxy.google.com - September 12 at 1:24 PM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:XENE)
biz.yahoo.com - September 9 at 7:47 PM
streetinsider.com logoXenon Pharmaceuticals (XENE) Prices $30M Common Stock Offering (NASDAQ:XENE)
www.streetinsider.com - September 8 at 12:07 PM
publicnow.com logoXenon Pharmaceuticals Announces Pricing of $30 Million Public Offering of Common Shares (NASDAQ:XENE)
www.publicnow.com - September 8 at 12:07 PM
finance.yahoo.com logo4:33 pm Xenon Pharmaceuticals announces proposed public offering of common shares by existing security holders (NASDAQ:XENE)
finance.yahoo.com - September 7 at 8:16 PM
publicnow.com logoXenon Pharmaceuticals Announces Proposed Public Offering of Common Shares (NASDAQ:XENE)
www.publicnow.com - September 7 at 8:16 PM
capitalcube.com logoXenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:XENE)
www.capitalcube.com - August 11 at 11:50 AM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 3-Aug-16 8:30pm GMT (NASDAQ:XENE)
finance.yahoo.com - August 8 at 8:34 PM
benzinga.com logoXenon Expects XEN801 Results In Q1 2017, Delayed One Quarter (NASDAQ:XENE)
www.benzinga.com - August 5 at 11:27 AM
sg.finance.yahoo.com logoXenon Pharmaceuticals reports 2Q loss (NASDAQ:XENE)
sg.finance.yahoo.com - August 3 at 8:45 PM
biz.yahoo.com logoQ2 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:XENE)
biz.yahoo.com - August 3 at 11:42 AM
finance.yahoo.com logoXenon Pharmaceuticals to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:XENE)
finance.yahoo.com - August 2 at 8:46 PM
publicnow.com logoXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update (NASDAQ:XENE)
www.publicnow.com - July 25 at 4:48 PM
publicnow.com logoXenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic Programs at the Jefferies 2016 Healthcare Conference (NASDAQ:XENE)
www.publicnow.com - June 8 at 7:58 AM
biz.yahoo.com logoXENON PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:XENE)
biz.yahoo.com - June 3 at 4:32 PM
publicnow.com logoXenon Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:XENE)
www.publicnow.com - June 2 at 8:25 AM
capitalcube.com logoXenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:XENE)
www.capitalcube.com - May 17 at 4:34 PM
sg.finance.yahoo.com logoXenon Pharmaceuticals reports 1Q loss (NASDAQ:XENE)
sg.finance.yahoo.com - May 10 at 5:28 PM
biz.yahoo.com logoXenon Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:XENE)
biz.yahoo.com - May 10 at 4:30 PM
publicnow.com logoXenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:XENE)
www.publicnow.com - May 10 at 4:18 PM
biz.yahoo.com logoQ1 2016 Xenon Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:XENE)
biz.yahoo.com - May 10 at 7:07 AM
publicnow.com logoXenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2016 Financial Results and Provide Corporate Update (NASDAQ:XENE)
www.publicnow.com - May 2 at 4:30 PM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 8-Mar-16 9:30pm GMT (NASDAQ:XENE)
finance.yahoo.com - April 7 at 11:41 AM
publicnow.com logoXenon Names Dr. Raymond J. Winquist as Head, Translational Research (NASDAQ:XENE)
www.publicnow.com - April 4 at 5:00 PM
feeds.benzinga.com logoXenon Pharma Will Offer Business, Milestone Update at Needham Conference (NASDAQ:XENE)
feeds.benzinga.com - March 31 at 5:22 PM
publicnow.com logoXenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference (NASDAQ:XENE)
www.publicnow.com - March 31 at 4:55 PM
thestreet.com logoXenon Pharmaceuticals To Host Conference Call And Webcast To Discuss 2015 Financial Results And Provide Corporate Update (NASDAQ:XENE)
www.thestreet.com - March 1 at 9:25 PM

Social

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Where is Xenon Pharmaceuticals' stock going? Where will Xenon Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 12 month price objectives for Xenon Pharmaceuticals' shares. Their predictions range from $13.00 to $20.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $16.30 in the next year.

When will Xenon Pharmaceuticals announce their earnings?

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about Xenon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xenon Pharmaceuticals stock:

  • According to Zacks Investment Research, "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. " (12/22/2016)

  • Jefferies Group LLC analysts commented, "XENE continues to make progress with PII data for XEN801 for mod-to-severe acne on-track for Q4’16 and PIIb data for postherpetic neuralgia for TV45070 in H1’17. This morning, Dermira reported positive PIIb data on DRM01 in acne, which we believe has a favorable read-thru for XEN801 since it operates on the same pathway (DRM01 more upstream). XEN801 may be able to derive greater activity given the dual mechanism that also induces apoptosis in sebocytes. XEN801 PIIa Data in Moderate-to-Severe Acne Expected in Q4: XEN801, a SCD1 inhibitor, is a potential tx of moderate-to-severe acne and is in a PII trial following positive PI data showing safety and tolerability, as well as good skin exposure and low systemic exposure. As previously disclosed, the PII trial is enrolling ~150 pts with moderate-to-severe acne who will apply XEN801 to the face for 12 wks, w/ 4-wk follow-up. The 1 EP will be percent change in total lesion count, including inflammatory and non-inflammatory, and topline data could be in Q4. This morning, we note that Dermira (DERM, NC) reported positive PIIb data for DRM01 in mod-to-severe acne, which we believe has a favorable read- thru to XEN801 since it operates on the same pathway (DRM01 is more upstream). XEN801 may be able to derive greater activity given the dual mechanism that also induces apoptosis in sebocytes." (5/11/2016)

Who owns Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (5.59%), Perceptive Advisors LLC (4.14%), Opaleye Management Inc. (2.26%), Interwest Venture Management Co. (1.79%), Novo A S (0.71%) and Renaissance Technologies LLC (0.64%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Ian Mortimer and Y Paul Goldberg.

Who sold Xenon Pharmaceuticals stock? Who is selling Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Opaleye Management Inc. and Scotia Capital Inc..

Who bought Xenon Pharmaceuticals stock? Who is buying Xenon Pharmaceuticals stock?

Xenon Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Interwest Venture Management Co. and Renaissance Technologies LLC.

How do I buy Xenon Pharmaceuticals stock?

Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Xenon Pharmaceuticals stock cost?

One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $7.75.

Xenon Pharmaceuticals (NASDAQ:XENE) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Earnings History Chart

Earnings by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Dividend History Chart

Dividend Payments by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Last Updated on 2/26/2017 by MarketBeat.com Staff